Light Therapy for Oral Mucositis: Your Questions Answered
If you've been reading about light therapy (photobiomodulation, or PBM) for mouth pain and ulcers during cancer treatment, you may have seen news about the first FDA-authorized device, the MuReva OM. Clients often ask me how the treatment I offer compares. This page answers that honestly, including the ways they are different, not just similar.
What the FDA-Authorized Device Is
In November 2025, the FDA authorized the MuReva OM, the first device specifically authorized for oral mucositis in the United States. It is a set of soft silicone mouthpieces that a patient holds in the mouth, which bathe the whole oral cavity in red light (660 nm) for 10 minutes, delivered at the hospital immediately before each radiation treatment (FDA authorization; MuReva).
Its authorization covers a specific situation: adults receiving radiation therapy for head and neck cancer where less than 75% of the oral cavity is in the radiation field. It is prescription-only, and its national rollout only began in late 2026.
The Honest Trade-Offs
Light reaching the mouth. A device inside the mouth delivers its full dose directly to the tissue being treated. Treating through the skin of the cheek means some light is absorbed before it reaches the mouth lining. This is why I use a dual-wavelength device (the near-infrared component penetrates deeper tissue better) and why I calculate and record the dose for every treatment field, rather than estimating.
Dose discipline. The international mucositis guidelines warn that PBM only works when treatment parameters are followed precisely. Hospital systems are engineered to make that automatic. In my practice, that precision comes from written protocols: every field measured, every dose calculated, every session and symptom tracked, and your oncology team kept informed.
Evidence status. The strongest research evidence supports intraoral light therapy for preventing mucositis during head-and-neck radiation and stem-cell transplant. For chemotherapy-only regimens and for treating ulcers that have already developed, no guideline body has yet made a formal recommendation — for hospital devices or mine (MASCC/ISOO guidelines). I will always tell you which category your situation falls into.
Why an Extra-Oral Option Exists at All
Because most patients can't get the hospital version. When UK researchers surveyed all 20 children's cancer centres, only 2 were offering light therapy. In the US, publicly documented programs are concentrated in a handful of major cancer centers, and the first FDA-authorized device is only now reaching hospitals, at a cost of roughly $20,000 per clinical system.
The NHS itself describes laser probes used both "inside your mouth or outside your mouth, close to your cheek" (NHS) — so treating from outside the mouth is a recognized clinical approach, not a shortcut I invented. It trades some dose at the target tissue for accessibility.
What I Ask of Every Client
· Your oncology team knows you are adding light therapy.
· We never aim light at a tumor site, the thyroid, or the eyes, and we review your medications first.
· You track your mouth symptoms, and escalate to your medical team if needed.
· Light therapy is a companion to your cancer care, never a replacement for any part of it.
If a MuReva system becomes available at your treatment center and you are in its authorized group, that is the first choice to discuss with your radiation oncologist. My service exists for the many patients for whom that isn't yet an option.
Tracy
https://blog.tracydonegan.org/blog/where-to-get-light-therapy-for-oral-mucositis-in-the-us
Tracy Donegan is a midwife and certified photobiomodulation practitioner (University of Montpellier training) based in Round Rock, Texas. This page is educational and describes a supportive-care service; it is not medical advice and does not replace care from your oncology team.
Sources
· FDA De Novo authorization, MuReva OM (DEN240077): https://www.accessdata.fda.gov/cdrh_docs/pdf24/DEN240077.pdf
· MuReva evidence page: https://murevapt.com/evidence/
· MASCC/ISOO oral mucositis guidelines (Zadik et al. 2019): https://pmc.ncbi.nlm.nih.gov/articles/PMC7540329/
· Polish Society for Laser Dentistry umbrella review (2025): https://dmp.umw.edu.pl/en/article/2025/62/6/1157
· UK CCLG PBM availability survey: https://pmc.ncbi.nlm.nih.gov/articles/PMC9715443/
· ONS Voice, PBM adoption in oral mucositis care (Sept 2026): https://www.ons.org/publications-research/voice/news-views/09-2026/photobiomodulation-shines-new-light-oral-mucositis-care
· NHS, Mucositis: https://www.nhs.uk/conditions/mucositis/
